Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada

Vanderkooi, Otto G; Scheifele, David W.; Girgenti, Douglas; Halperin, Scott A.; Patterson, Scott D.; Gruber, William C.; Emini, Emilio A.; Scott, Daniel A.; Kellner, James D.

doi:10.1097/inf.0b013e318233049d

Cited by 50 publications

(31 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent post-licensure, indirect cohort study, an antibody concentration against serotype 19A of 1 mg/ml was shown to be adequate to prevent most of the IPD cases due to this serotype [37]. This antibody level was in the range of values produced by PCV13 after both the infant series and the booster dose, independent of the schedule used, as clearly shown by Rodgers et al, who analyzed several immunogenicity studies in which PCV13 was administered on the 2 + 1 schedule [14] and by several authors who have studied PCV13 on the 3 + 1 schedule [38][39][40]. Conversely, the very good results shown by some of the studies that have evaluated PCV10 are surprising and difficult to explain when the putative correlate of protection for serotype 19A and the amount of functioning cross-reactive antibodies produced by conjugate serotype 19F included in PCV10 are considered.…”

Section: Expert Commentarymentioning

confidence: 84%

The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease

Principi

Esposito

2015

Expert Review of Vaccines

View full text Add to dashboard Cite

The circulation in the community of pneumococcal serotype 19A, a highly invasive and frequently extremely resistant pneumococcal strain, has increased the focus on methods to control its presence and effect. Two vaccines have been developed: the 10-valent pneumococcal conjugate vaccine (PCV10) and the 13-valent pneumococcal conjugate vaccine (PCV13). Available data indicate that PCV13 is highly effective in reducing the risk of serotype 19A invasive pneumococcal disease (IPD) in both vaccinated children and unvaccinated adults. Positive data have also been published for PCV10 that suggest that the conjugated serotype 19F included in the vaccine could evoke a cross-reactive antibody response with serotype 19A. However, a great number of invasive pneumococcal disease (IPD) cases are associated with serotypes not included in either of the vaccines, and preparation of a vaccine containing all the serotypes is unrealistic. Protein vaccines are the real future to definitively reduce the pneumococcal disease burden.

show abstract

Section: Expert Commentarymentioning

confidence: 84%

The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease

Principi

Esposito

2015

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…[11] In addition, given the immunogenicity studies of PCV13 the immune responses for serotype 3 differ from that for the other serotypes: lower antibody titers and no or little booster effect (but no hyporesponsiveness). [18][19][20][21][22] 6 *χ 2 for trend P=0.031 Nevertheless, the response for serotype 3 on opsonophagocytic activity assay is high when the infant series and toddler dose of PCV13 is used. [19,20] There is a recent report on a three-year-old girl who developed a parapneumonic empyema caused by serotype 3, while she was fully vaccinated with PCV13, but in a 2 þ 1 schedule.…”

Section: Discussionmentioning

confidence: 94%

Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine

Syrogiannopoulos

Michoula

Tsimitselis

et al. 2016

Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…The limited effectiveness of PCV-7 was reported in Utah as a result of the rapid emergence of IPD, particularly empyema, due to non-PCV-7 serotypes (10,19,39,40). These findings encouraged the development of new pneumococcal conjugate vaccines with additional serotypes, namely, PCV-10 and PCV-13 (41,42). However, clinical trials showing the efficacy of PCV-10 and PCV-13 against consolidated pneumonia and IPD have been limited.…”

Section: Discussionmentioning

confidence: 98%

Distribution of Streptococcus pneumoniae Serotypes That Cause Parapneumonic Empyema in Turkey

Ceyhan

Özsürekçi

Gürler

et al. 2013

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Streptococcus pneumoniae is the most common etiological cause of complicated pneumonia, including empyema. In this study, we investigated the serotypes of S. pneumoniae that cause empyema in children. One hundred fifty-six children who were diagnosed with pneumonia complicated with empyema in 13 hospitals in seven geographic regions of Turkey between 2010 and 2012 were included in this study. Pleural fluid samples were collected by thoracentesis and tested for 14 serotypes/serogroups using a Bio-Plex multiplex antigen detection assay. The serotypes of S. pneumoniae were specified in 33 of 156 samples. The mean age ؎ the standard deviation of the 33 patients was 6.17 ؎ 3.54 years (range, 0.6 to 15 years). All of the children were unvaccinated according to the vaccination reports. Eighteen of the children were male, and 15 were female. The serotypes of the non-7-valent pneumococcal conjugated vaccine (non-PCV-7), serotype 1, serotype 5, and serotype 3, were detected in eight (14.5%), seven (12.7%), and five (9.1%) of the samples, respectively. Serotypes 1 and 5 were codetected in two samples. The remaining non-PCV-7 serotypes were 8 (n ‫؍‬ 3), 18 (n ‫؍‬ 1), 19A (n ‫؍‬ 1), and 7F/A (n ‫؍‬ 1). PCV-7 serotypes 6B, 9V, 14, 19F, and 23F were detected in nine (16.3%) of the samples. The potential serotype coverages of PCV-7, PCV-10, and PCV-13 were 16.3%, 45.4%, and 60%, respectively. Pediatric parapneumonic empyema continues to be an important health problem despite the introduction of conjugated pneumococcal vaccines. Active surveillance studies are needed to monitor the change in S. pneumoniae serotypes that cause empyema in order to have a better selection of pneumococcal vaccines.

show abstract

Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada

Abstract: Responses to routine childhood vaccines did not differ with PCV7 or PCV13 coadministration. Serotype-specific pneumococcal antibody concentrations were protective. The safety profile of PCV13 was favorable.

Cited by 50 publications

References 21 publications

The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease

The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease

Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine

Distribution of Streptococcus pneumoniae Serotypes That Cause Parapneumonic Empyema in Turkey

Contact Info

Product

Resources

About